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Visitors
Prof  SAZER, Shelley Baylor College of Medicine, USA, 28 September 2005
Prof  HAN, Kyou Hoon Korea Research Institute of Bioscience and Biotechnology, Korea, 8 November 2005
Prof  SUZUKI, Hisanori      University of Verona, Italy, 30 November 2005
In human history, small organic molecules have been utilized for improving human health and for revealing secrets 
of life. Discovery or design of small organic molecules with unique biological activity permits small-molecule-initiated 
exploration of biology and further understanding of human diseases. Our laboratory has been discovering small organic 
molecules that modulate transcription or differentiation to use them as tools to explore biology.  Such chemistry-initiated 
biology is recently called chemical biology, an emerging ﬁ eld of biology and medical sciences. Although our chemical 
biology is a basic one, it may “catalyze” future drug discovery.
Scope of Re search
Presentations
Chemical Biology of Gene Expression and Cell Differen-
tiation, Uesugi M, 78th National Meeting of Japanese So-
ciety of Pharmacology, Yokohama, Japan, 22 - 24 March 
2005.
Modulation of Gene Expression by Targeting a Protein-
protein Interaction, Uesugi M, 12th International Molecu-
lar Medicine Tri-Conference, San Francisco, USA, 19 - 22 
April 2005.
Synthetic Small Molecules that Modulate Gene Expres-
sion and Cell Differentiation, Uesugi M, 20th International 
Combinatorial Chemistry Symposium, Osaka, Japan, 25 - 
26 April 2005.
Poly(ADP-ribose)polymerase-1 Activation and Mito-
chondrial Impairment in vitro Model of Cerebral Ischemia, 
Tanaka S, 20th Biennial Meeting of the ISN Satellite Sym-
posium “Molecular Basis for Signal Transduction in Neu-
rodegeneration and Neuroregeneration”, Warsaw, Poland, 
26 August - 1 September 2005.
Poly(ADP-ribose)polymerase-1 Activation and Mi-
tochondrial Impairment in in vitro Model of Cerebral 
ischemia, Tanaka S, 18th National Convention on ADP-
ribosylation Process, Verona, Italy, 3 - 4 October 2005.
Regulation of NF-κB and AP-1 by PARP-1 in Reactive
Astrocytes of Alzheimer’s Disease, Tanaka S, 14th 
International Meeting of ADP Ribosylation Reactions, 
“PARP2005: Bench to Bedside”, Newcastle, UK, 5 - 7 
October 2005.
Chemical Biology of Gene Expression and Cell Differ-
entiation, Uesugi M, 6th Australian Peptide Conference, 
Hamilton Island, Queensland, Australia, 9 - 14 October 
2005.
Chemical Biology of Gene Expression and Cell Differen-
tiation, Uesugi M, Paciﬁ chem 2005 Symposium, “Chemical 
Biology: Small Chemical Compounds As Magic Bullets 
To Elucidate Biological Mechanisms”, Honolulu, Hawaii, 
15 - 20 December 2005.  
Grants
Uesugi M, Small Molecule Transcription Factors that 
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Top ics
Small-Molecule-initiated Biology
Our current research programs focus on discovering 
and designing small organic molecules that modulate gene 
transcription or cell differentiation and using them as tools 
to explore biology.  Regulation of gene transcription and 
cell differentiation often induces drastic phenotypic chang-
es in living organisms. Precise, external control over these 
endogenous processes through small organic molecules 
represents a challenge of chemistry to nature. The latest 
achievements are summarized below.
Discovery of organic compounds that modulate tran-
scription.  Our group isolated human Sur-2, a Ras-linked 
subunit of the human mediator complex, as a nuclear fac-
tor that plays a critical role in overexpression of Her2 in 
breast cancer cells. This achievement was well appreciated 
in the oncology ﬁ eld because Her2 is a clinically important 
oncogene whose overexpression occurs in ~30% of breast 
cancer patients.  Our group showed, by a combination of 
biochemical and NMR experiments, that Sur-2 protein 
interacts with a short alpha-helical motif in the activation 
domain of ESX transcription factor to activate Her2 tran-
scription.
We also discovered a small-molecule inhibitor of the 
ESX-Sur2 interaction by a screening of a focused chemi-
cal library. The compound that we named “adamanolol” 
represents the first small molecules that modulate gene 
transcription by targeting transcription factor-coactivator 
interaction. Our group, as a collaboration with another 
laboratory, synthesized adamanolol and its derivatives and 
obtained structure-activity relationship, which enabled 
the design of the second-generation compound named 
“wrenchnolol.”  The wrench-shaped compound is now rec-
ognized in the ﬁ eld as a highly unique synthetic molecule 
that controls gene expression.
Wrenchnolol mimics an alpha-helical activation do-
main of ESX: it may serves as a small-molecule activation 
module when coupled with a DNA binding molecule.  Our 
group, as a collaboration with Dervan’s group, has recently 
succeeded in designing a completely organic, synthetic 
transcription factor that activates transcription. This work 
demonstrates that it is possible to generate a transcription 
factor out of organic compounds.
Discovery of organic molecules that modulate cell dif-
ferentiation.  Our group has developed a unique method of 
screening chemical libararies for the discovery of bioactive 
molecules.  In our approach, chemical compounds were 
first profiled by their effects on phenotypic fat cell dif-
ferentiation and pre-selected for more focused secondary 
assays.  This approach enebled us to discover a number 
of bioactive compounds with interesting biological activi-
ties, and these molecules are now used for elucidation of 
new biological pathways in our group. For example, we 
recently discovered a new signaling pathway to control 
insulin/IGF pathways by utilizing the compound we call 
chromeceptin.
Roles of Poly(ADP-ribose) polymerase-1 in 
Alzheimer’s Disease
Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear 
enzyme that catalyzes formation of (ADP-ribose)n chains 
on acceptor proteins including histones and PARP-1 itself. 
PARP-1 is termed a “guardian of the genome”, because 
it assists DNA repair by sensing DNA damage.  In the 
present year, our group investigated a role of PARP-1 in 
transcriptional regulation and Alzheimer’s disease (AD) 
pathogenesis. Our group examined the effects of PARP-1 
siRNA on the DNA-binding activities of a range of tran-
scription factors.  Among transcription factors examined, 
NF-κB and AP-1 were found to increase their DNA bind-
ing activity in astrocytes after the addition of β-amyloid, 
whereas the increase of their DNA-binding was suppressed 
by PARP-1 siRNA in a dose-dependent manner. NF-κB 
and AP-1 are the transcription factors involved primarily in 
expression of proinﬂ ammatory or cytotoxic factors in AD 
astrocytes, and PARP-1 plays a critical role as a coactivator 
in their transcriptional activation.  It is an exciting prospect 
that manipulation of the PARP-1 expression may serve as 
a novel therapeutic intervention in the treatment of AD.
can be Used for Biological Investigation, Precursory Re-
search for Embryonic Science and Technology, Japan Sci-
ence and Technology Agency, 1 October 2005 - 31 March 
2009.
Tanaka S, Study on the Function of NAD+ and ADP-
ribose as Stress Mediator, Japan Foundation for Applied 
Enzymology, 1 April 2005 - 31 March 2006. 
